← 홈

난소암

353개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 353개
CGTBiologicSung-Soo ParkPreclinical

IMiD treatment (IMiD treatment)

Multiple Myeloma, Relapsed; Multiple Myeloma (MM) · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+5
효능 ORR 48.3%임상시험 39상태 RECRUITING
ADCBiologicSanofiPhase 2

Belumosudil (Belumosudil)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 74%임상시험 38상태 RECRUITING
CGTBiologicNovartis PharmaceuticalsPhase 2

CTL019 T-cells (CTL019 T-cells)

B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 82.3%임상시험 37상태 ACTIVE
CGTBiologicHe HuangPhase 1

CAR-T cells chimeric antigen receptor T cells (CAR-T cells chimeric antigen receptor T cells)

Relapsed/Refractory Acute Myeloid Leukemia(AML) · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
효능 0%임상시험 32상태 RECRUITING
AntibodyRocheVedotin-Based Polatuzumab V…Phase 2

rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+5
효능 ORR 76%임상시험 32상태 RECRUITING
AntibodyRocheVedotin in Relapsed/Refract…Phase 2

Glofitamab/Obinutuzumab (Glofitamab/Obinutuzumab)

Richter Syndrome · FRα

#FR#Antibody#Phase2#항체#면역항체+5
효능 ORR 35.3%임상시험 31상태 RECRUITING
AntibodyMerck Sharp & Dohme LLCADCsPhase 3

H1 receptor antagonist (H1 receptor antagonist)

Ovarian Cancer; Fallopian Tube Cancer · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Phase3#항체#면역항체+5
효능 ORR 6%임상시험 31상태 RECRUITING
AntibodyMerck Sharp & Dohme LLCPhase 3

H2 receptor antagonist (H2 receptor antagonist)

Ovarian Cancer; Fallopian Tube Cancer · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Phase3#항체#면역항체+4
임상시험 31상태 RECRUITING
ADCBiologicstaleOHSU Knight Cancer InstitutePhase 1

Losartan (Losartan)

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8 · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4
임상시험 31상태 DISCONTINUED
ADCBiologicstaleAbbViePhase 2

Lubricating Eye Drops (Lubricating Eye Drops)

Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive · Recurrent Ovarian Cancer

#RecurrentOvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 0.02%임상시험 31상태 RECRUITING
CGTBiologicstaleMedigene AGPhase 1

MDG1015 (TCR-T cells, TCR-T cells (MDG1015))

Epithelial Ovarian Cancer; Gastro-esophageal Junction Cancer · Epithelial Ovarian Cancer

#EpithelialOvarianCancer#CGT#Phase1#세포유전치료#CAR-T+3
효능 ORR 4%임상시험 31상태 RECRUITING
ADCBiologicstaleOHSU Knight Cancer InstitutePhase 1

Tretinoin (Tretinoin)

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8 · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 100%임상시험 31상태 DISCONTINUED
ADCBiologicstaleMylan Pharmaceuticals IncPhase 1

Verapamil (Verapamil)

Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 31상태 ACTIVE
ADCBiologicstaleVerastem, Inc.Phase 2

Defactinib (Defactinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 3.2%임상시험 30상태 RECRUITING
ADCBiologicstaleJanssen Research & Development,…Phase 2

Erdafitinib (Erdafitinib)

Muscle Invasive Bladder Urothelial Carcinoma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 46.9%임상시험 30상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab cohort 1)

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 7%임상시험 30상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab cohort 2)

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 37.8%임상시험 30상태 RECRUITING
ADCBiologicstaleCalithera Biosciences, IncPhase 2

Sapanisertib (Sapanisertib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 18.4%임상시험 30상태 RECRUITING
AntibodystaleMarcela V. Maus, M.D.,Ph.D.Phase 2

Emapalumab (Emapalumab)

Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 60%임상시험 29상태 RECRUITING
ADCBiologicstaleAbbViePhase 3

MIRV (Mirvetuximab Soravtansine, Mirvetuximab Soravtansine (MIRV))

Epithelial Ovarian Cancer · Epithelial Ovarian Cancer

#EpithelialOvarianCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 100%임상시험 28상태 RECRUITING

4 / 18 페이지

← 이전다음 →